Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inobrodib + azacitidine
- Development stage
- Phase 2
- Lead developer
- CellCentric
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Subcutaneous
01
Overview
**Inobrodib + azacitidine** is an investigational combination therapy currently in clinical development for hematologic malignancies (including acute myeloid leukemia and high-risk myelodysplastic syndrome). Inobrodib is a potent, selective, orally bioavailable small-molecule inhibitor of the bromodomains of CBP and EP300, which are histone acetyltransferases crucial for transcriptional regulation of cancer-driving genes such as MYC and IRF4. Azacitidine is a hypomethylating agent and a pyrimidine nucleoside analog, which inhibits DNA methyltransferase, leading to DNA hypomethylation and reactivation of silenced genes involved in differentiation and apoptosis. The combination aims to enhance anti-tumor activity by simultaneously modulating chromatin structure, gene expression, and DNA methylation status.
- Other names
- inobrodibCCS1477CCS-1477CCS 1477azacitidine
02
Targets
CREBBP BD (Creb-binding protein bromodomain)DNMT1 (DNA (cytosine-5)-methyltransferase 1)EP300 BD (E1A Binding Protein p300 Bromodomain)CREBBP (CREB-binding protein)
Beyond the preview
Go deeper on inobrodib + azacitidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inobrodib + azacitidine.